$MOH
MOLINA HEALTHCARE, INC.

2020 Q4 Form 10-Q Financial Statement

#000117992920000139 Filed on October 29, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $5.235B $5.021B $4.243B
YoY Change 22.48% 18.34% -9.67%
Cost Of Revenue $4.408B $4.098B $3.523B
YoY Change 24.34% 16.32% -9.69%
Gross Profit $827.0M $923.0M $561.0M
YoY Change 43.08% 64.53% -0.88%
Gross Profit Margin 15.8% 18.38% 13.22%
Selling, General & Admin $690.0M $608.0M $442.0M
YoY Change 48.39% 37.56% -12.99%
% of Gross Profit 83.43% 65.87% 78.79%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $24.00M $23.00M $21.00M
YoY Change 14.29% 9.52% -32.26%
% of Gross Profit 2.9% 2.49% 3.74%
Operating Expenses $714.0M $631.0M $463.0M
YoY Change 46.91% 36.29% -13.13%
Operating Profit $113.0M $289.0M $257.0M
YoY Change 22.83% 12.45% -12.88%
Interest Expense -$30.00M $27.00M $22.00M
YoY Change 50.0% 22.73% -15.38%
% of Operating Profit -26.55% 9.34% 8.56%
Other Income/Expense, Net -$27.00M -$24.00M
YoY Change 12.5% -33.33%
Pretax Income $51.00M $262.0M $233.0M
YoY Change -77.03% 12.45% -10.04%
Income Tax $17.00M $77.00M $58.00M
% Of Pretax Income 33.33% 29.39% 24.89%
Net Earnings $34.00M $185.0M $175.0M
YoY Change -79.76% 5.71% -11.17%
Net Earnings / Revenue 0.65% 3.68% 4.12%
Basic Earnings Per Share $3.14 $2.81
Diluted Earnings Per Share $566.7K $3.10 $2.75
COMMON SHARES
Basic Shares Outstanding 59.30M shares 58.70M shares 62.20M shares
Diluted Shares Outstanding 59.60M shares 63.60M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.029B $4.965B $4.436B
YoY Change 37.09% 11.93% -4.11%
Cash & Equivalents $4.154B $3.196B $2.679B
Short-Term Investments $1.875B $1.769B $1.757B
Other Short-Term Assets $175.0M $213.0M $161.0M
YoY Change 7.36% 32.3% -87.89%
Inventory
Prepaid Expenses
Receivables $1.672B $1.775B $1.280B
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.876B $6.953B $5.877B
YoY Change 31.99% 18.31% -19.5%
LONG-TERM ASSETS
Property, Plant & Equipment $462.0M $395.0M $379.0M
YoY Change 2.67% 4.22% 43.56%
Goodwill $692.0M
YoY Change 383.92%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $119.0M $101.0M $108.0M
YoY Change 13.33% -6.48% 260.0%
Total Long-Term Assets $1.656B $928.0M $824.0M
YoY Change 101.95% 12.62% 9.87%
TOTAL ASSETS
Total Short-Term Assets $7.876B $6.953B $5.877B
Total Long-Term Assets $1.656B $928.0M $824.0M
Total Assets $9.532B $7.881B $6.701B
YoY Change 40.44% 17.61% -16.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $608.0M $566.0M $442.0M
YoY Change 44.08% 28.05% -46.36%
Accrued Expenses $21.00M $28.00M
YoY Change -16.0%
Deferred Revenue $375.0M $61.00M $207.0M
YoY Change 50.6% -70.53% 16.29%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $23.00M
YoY Change -100.0% -92.23%
Total Short-Term Liabilities $4.965B $3.556B $3.308B
YoY Change 51.88% 7.5% -36.54%
LONG-TERM LIABILITIES
Long-Term Debt $2.127B $1.813B $1.239B
YoY Change 71.95% 46.33% 21.59%
Other Long-Term Liabilities $119.0M $85.00M $90.00M
YoY Change 32.22% -5.56% 50.0%
Total Long-Term Liabilities $2.246B $1.898B $1.329B
YoY Change 69.25% 42.81% 23.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.965B $3.556B $3.308B
Total Long-Term Liabilities $2.246B $1.898B $1.329B
Total Liabilities $7.436B $5.680B $4.870B
YoY Change 54.05% 16.63% -24.96%
SHAREHOLDERS EQUITY
Retained Earnings $1.860B $1.983B $1.666B
YoY Change 4.44% 19.03% 105.43%
Common Stock $199.0M $181.0M $160.0M
YoY Change 13.71% 13.13% -78.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.096B $2.201B $1.831B
YoY Change
Total Liabilities & Shareholders Equity $9.532B $7.881B $6.701B
YoY Change 40.44% 17.61% -16.77%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income $34.00M $185.0M $175.0M
YoY Change -79.76% 5.71% -11.17%
Depreciation, Depletion And Amortization $24.00M $23.00M $21.00M
YoY Change 14.29% 9.52% -32.26%
Cash From Operating Activities $1.299B -$158.0M $242.0M
YoY Change 4379.31% -165.29% -147.92%
INVESTING ACTIVITIES
Capital Expenditures -$10.00M -$19.00M -$10.00M
YoY Change -62.96% 90.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities -$488.0M $79.00M $323.0M
YoY Change 162.37% -75.54% -25.4%
Cash From Investing Activities -$498.0M $60.00M $313.0M
YoY Change 133.8% -80.83% -26.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 156.0M -2.000M -148.0M
YoY Change -471.43% -98.65% -70.92%
NET CHANGE
Cash From Operating Activities 1.299B -158.0M 242.0M
Cash From Investing Activities -498.0M 60.00M 313.0M
Cash From Financing Activities 156.0M -2.000M -148.0M
Net Change In Cash 957.0M -100.0M 407.0M
YoY Change -523.45% -124.57% -168.87%
FREE CASH FLOW
Cash From Operating Activities $1.299B -$158.0M $242.0M
Capital Expenditures -$10.00M -$19.00M -$10.00M
Free Cash Flow $1.309B -$139.0M $252.0M
YoY Change 2237.5% -155.16% -150.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001179929
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 USD
CY2019Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 USD
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 USD
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 USD
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0 USD
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31719
dei Entity Registrant Name
EntityRegistrantName
MOLINA HEALTHCARE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-4204626
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Oceangate, Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Long Beach,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90802
dei City Area Code
CityAreaCode
562
dei Local Phone Number
LocalPhoneNumber
435-3666
dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value
dei Trading Symbol
TradingSymbol
MOH
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59300000 shares
CY2020Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
4768000000 USD
CY2019Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
4084000000 USD
CY2020Q3 us-gaap Revenues
Revenues
5021000000 USD
us-gaap Premiums Earned Net
PremiumsEarnedNet
13444000000 USD
us-gaap Premiums Earned Net
PremiumsEarnedNet
12085000000 USD
CY2020Q3 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
170000000 USD
CY2019Q3 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
119000000 USD
moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
477000000 USD
moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
367000000 USD
CY2020Q3 moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
69000000 USD
CY2019Q3 moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
0 USD
moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
206000000 USD
moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
0 USD
CY2020Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
14000000 USD
CY2019Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
40000000 USD
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
61000000 USD
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
103000000 USD
CY2019Q3 us-gaap Revenues
Revenues
4243000000 USD
us-gaap Revenues
Revenues
14188000000 USD
moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
0 USD
us-gaap Revenues
Revenues
12555000000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4098000000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3523000000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11412000000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10360000000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
368000000 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
323000000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1030000000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
953000000 USD
CY2020Q3 moh Premium Tax Expenses
PremiumTaxExpenses
170000000 USD
CY2019Q3 moh Premium Tax Expenses
PremiumTaxExpenses
119000000 USD
moh Premium Tax Expenses
PremiumTaxExpenses
477000000 USD
moh Premium Tax Expenses
PremiumTaxExpenses
367000000 USD
CY2020Q3 moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
70000000 USD
CY2019Q3 moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
0 USD
moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
209000000 USD
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
23000000 USD
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
21000000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
64000000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
68000000 USD
CY2020Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
3000000 USD
CY2019Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
0 USD
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
9000000 USD
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
5000000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
4732000000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
3986000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
13201000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
11753000000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
289000000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
257000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
987000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
802000000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
27000000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
22000000 USD
us-gaap Interest Expense
InterestExpense
72000000 USD
us-gaap Interest Expense
InterestExpense
67000000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27000000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-77000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-52000000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
262000000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
233000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
910000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
750000000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
58000000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
271000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
181000000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
175000000 USD
us-gaap Net Income Loss
NetIncomeLoss
639000000 USD
us-gaap Net Income Loss
NetIncomeLoss
569000000 USD
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.14
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
10.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.15
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.10
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
10.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.80
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
185000000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
175000000 USD
us-gaap Net Income Loss
NetIncomeLoss
639000000 USD
us-gaap Net Income Loss
NetIncomeLoss
569000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
6000000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
43000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
17000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
1000000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
10000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
4000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5000000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
33000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
13000000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
190000000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
175000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
672000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
582000000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3196000000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2452000000 USD
CY2020Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1769000000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1946000000 USD
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
1775000000 USD
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1406000000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
213000000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
163000000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
6953000000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
5967000000 USD
CY2020Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
395000000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
385000000 USD
CY2020Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
265000000 USD
CY2019Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
172000000 USD
CY2020Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
93000000 USD
CY2019Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
79000000 USD
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
74000000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
79000000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
101000000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
105000000 USD
CY2020Q3 us-gaap Assets
Assets
7881000000 USD
CY2019Q4 us-gaap Assets
Assets
6787000000 USD
CY2020Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
2289000000 USD
CY2019Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1854000000 USD
CY2020Q3 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
640000000 USD
CY2019Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
664000000 USD
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
566000000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
502000000 USD
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
61000000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
249000000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3556000000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3269000000 USD
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1813000000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1237000000 USD
CY2020Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
226000000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
231000000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
85000000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
90000000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
5680000000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
4827000000 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59000000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62000000 shares
CY2020Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 USD
CY2019Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 USD
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
181000000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
175000000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
37000000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1983000000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1781000000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2201000000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1960000000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7881000000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6787000000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1960000000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
178000000 USD
CY2020Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
446000000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-30000000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-19000000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4000000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1647000000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
276000000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
47000000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
26000000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1996000000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
185000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5000000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
15000000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2201000000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1647000000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
198000000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-103000000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5000000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3000000 USD
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1835000000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
196000000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-321000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
8000000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
18000000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1736000000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
175000000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-90000000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
10000000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1831000000 USD
us-gaap Net Income Loss
NetIncomeLoss
639000000 USD
us-gaap Net Income Loss
NetIncomeLoss
569000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
68000000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
3000000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-7000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
43000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
29000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
15000000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
2000000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
369000000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-50000000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
98000000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6000000 USD
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
431000000 USD
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
14000000 USD
moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
-24000000 USD
moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
-355000000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
55000000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
37000000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-188000000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4000000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
34000000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
4000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
591000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
398000000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
670000000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1938000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
891000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1890000000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
62000000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30000000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3000000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
2000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
98000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-80000000 USD
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
789000000 USD
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
600000000 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
453000000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
380000000 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
220000000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
30000000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
514000000 USD
moh Cash Paid For Settlement Of Conversion Option
CashPaidForSettlementOfConversionOption
27000000 USD
moh Cash Paid For Settlement Of Conversion Option
CashPaidForSettlementOfConversionOption
578000000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
27000000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
578000000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
12000000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
240000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-5000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
24000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
69000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-510000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
758000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-192000000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2508000000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2926000000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3266000000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2734000000 USD
us-gaap Stock Issued1
StockIssued1
8000000 USD
us-gaap Stock Issued1
StockIssued1
7000000 USD
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
106000000 USD
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
moh Fair Value Of Contingent Consideration Liabilities Assumed In Noncash Investing Or Financing Activities
FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities
40000000 USD
moh Fair Value Of Contingent Consideration Liabilities Assumed In Noncash Investing Or Financing Activities
FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities
0 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
4000000 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
62000000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of medical claims and benefits payable of our Health Plans segment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health Plans segment contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health Plans segment quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Settlements under risk- or savings-sharing programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchase price allocations relating to business combinations, including the determination of contingent consideration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The assessment of long-lived and intangible assets, and goodwill for impairment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for the outcome of litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of valuation allowances for deferred tax assets; and</span></div>•The determination of unrecognized tax benefits.
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3196000000 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2679000000 USD
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
70000000 USD
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3266000000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2734000000 USD
moh Investments Maturity Period
InvestmentsMaturityPeriod
P10Y
moh Investments Average Maturity Period
InvestmentsAverageMaturityPeriod
P10Y
CY2020Q3 us-gaap Interest Receivable
InterestReceivable
9000000 USD
CY2019Q4 us-gaap Interest Receivable
InterestReceivable
12000000 USD
CY2020Q3 moh Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
136000000 USD
CY2019Q4 moh Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
92000000 USD
CY2020Q3 moh Amounts Due To Government Agencies Medicaid Other
AmountsDueToGovernmentAgenciesMedicaidOther
83000000 USD
CY2019Q4 moh Amounts Due To Government Agencies Medicaid Other
AmountsDueToGovernmentAgenciesMedicaidOther
95000000 USD
CY2020Q3 moh Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
38000000 USD
CY2019Q4 moh Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
14000000 USD
CY2020Q3 moh Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
35000000 USD
CY2019Q4 moh Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
36000000 USD
CY2020Q3 moh Other Medicare Program
OtherMedicareProgram
30000000 USD
CY2019Q4 moh Other Medicare Program
OtherMedicareProgram
21000000 USD
CY2020Q3 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
265000000 USD
CY2019Q4 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
368000000 USD
CY2020Q3 moh Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold
AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
33000000 USD
CY2019Q4 moh Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold
AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
15000000 USD
CY2020Q3 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
20000000 USD
CY2019Q4 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
23000000 USD
CY2020Q3 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
640000000 USD
CY2019Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
664000000 USD
CY2020Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
265000000 USD
CY2020Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
59000000 USD
CY2020Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
206000000 USD
CY2020Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable Payable Current Year
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear
230000000 USD
CY2020Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable Receivable Prior Years
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears
24000000 USD
CY2019Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
368000000 USD
CY2019Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
63000000 USD
CY2019Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
305000000 USD
CY2020Q3 moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
69000000 USD
CY2019Q3 moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
47000000 USD
moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
195000000 USD
moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
138000000 USD
CY2020Q3 moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
63000000 USD
CY2019Q3 moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
46000000 USD
moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
180000000 USD
moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
109000000 USD
CY2020Q3 moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
19000000 USD
CY2019Q3 moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
5000000 USD
moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
23000000 USD
moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
35000000 USD
CY2020Q3 moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
82000000 USD
CY2019Q3 moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
51000000 USD
moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
203000000 USD
moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
144000000 USD
CY2020Q3 moh Quality Incentive Premium Revenue As A Percentage Of Total Revenue
QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
0.017
CY2019Q3 moh Quality Incentive Premium Revenue As A Percentage Of Total Revenue
QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
0.012
moh Quality Incentive Premium Revenue As A Percentage Of Total Revenue
QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
0.015
moh Quality Incentive Premium Revenue As A Percentage Of Total Revenue
QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
0.012
CY2020Q1 moh Health Care Insurance Fee Liability
HealthCareInsuranceFeeLiability
271000000 USD
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
1775000000 USD
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1406000000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentrations of Credit RiskFinancial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate.
moh Investments Maturity Period
InvestmentsMaturityPeriod
P10Y
moh Investments Maturity Period
InvestmentsMaturityPeriod
P10Y
CY2020Q3 moh Health Care Insurance Fee Liability
HealthCareInsuranceFeeLiability
277000000 USD
CY2020Q2 moh Increase Decrease In Health Insurance Fee Liability
IncreaseDecreaseInHealthInsuranceFeeLiability
6000000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
185000000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
175000000 USD
us-gaap Net Income Loss
NetIncomeLoss
639000000 USD
us-gaap Net Income Loss
NetIncomeLoss
569000000 USD
CY2020Q2 us-gaap Shares Outstanding
SharesOutstanding
58700000 shares
CY2019Q2 us-gaap Shares Outstanding
SharesOutstanding
62200000 shares
CY2019Q4 us-gaap Shares Outstanding
SharesOutstanding
61900000 shares
CY2018Q4 us-gaap Shares Outstanding
SharesOutstanding
62100000 shares
moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
100000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
2800000 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2020Q3 moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
0 shares
CY2019Q3 moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
0 shares
moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
100000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58700000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62200000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59200000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62200000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
800000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1800000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
900000 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
600000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
800000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
600000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59600000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63600000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60000000.0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64600000 shares
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.14
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
10.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.15
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.10
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
10.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.80
CY2020Q3 moh Business Combination Number Of Business Combinations
BusinessCombinationNumberOfBusinessCombinations
2 business_combination
CY2020Q3 moh Business Combination Number Of Business Combinations
BusinessCombinationNumberOfBusinessCombinations
2 business_combination
us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P10Y8M12D
CY2020Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
47000000 USD
CY2020Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1769000000 USD
CY2020Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
40000000 USD
CY2020Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
40000000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1946000000 USD
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1975000000 USD
CY2019Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
29000000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1721000000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1769000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1941000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1946000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
193000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
195000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
943000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
975000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
160000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
165000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
425000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
434000000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1721000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
1769000000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
6000000 USD
CY2019Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
11000000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
11000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
139000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
25 Security
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
365000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
239 Security
CY2020Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
93000000 USD
CY2020Q3 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
91000000 USD
CY2020Q3 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
2000000 USD
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (“IBNP”)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div>
CY2020Q3 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
1615000000 USD
CY2019Q4 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
1406000000 USD
CY2020Q3 moh Pharmacy Claims Payable
PharmacyClaimsPayable
148000000 USD
CY2019Q4 moh Pharmacy Claims Payable
PharmacyClaimsPayable
126000000 USD
CY2020Q3 moh Capitation Claims Payable
CapitationClaimsPayable
73000000 USD
CY2019Q4 moh Capitation Claims Payable
CapitationClaimsPayable
55000000 USD
CY2020Q3 moh Other Claims Payable
OtherClaimsPayable
453000000 USD
CY2019Q4 moh Other Claims Payable
OtherClaimsPayable
267000000 USD
CY2020Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
2289000000 USD
CY2019Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1854000000 USD
CY2020Q3 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
168000000 USD
CY2019Q4 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
132000000 USD
CY2019Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1854000000 USD
CY2018Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1961000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
11478000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
10613000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-66000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-253000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
11412000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
10360000000 USD
moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
50000000 USD
moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
131000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
9500000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
8996000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
1527000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
1481000000 USD
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
11027000000 USD
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
10477000000 USD
CY2020Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
2289000000 USD
CY2019Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1975000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-66000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-253000000 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
0 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
18000000 USD
CY2020Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
17000000 USD
CY2019Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
7000000 USD
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1813000000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1237000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5000000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000000 USD
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
15000000 USD
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
10000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
43000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
29000000 USD
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
76000000 USD
moh Unrecognized Compensation Forfeited Rate
UnrecognizedCompensationForfeitedRate
0.115
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
moh Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
65000000 USD
moh Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
51000000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
22000000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
20000000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2020Q3 us-gaap Revenues
Revenues
5021000000 USD
CY2019Q3 us-gaap Revenues
Revenues
4243000000 USD
us-gaap Revenues
Revenues
14188000000 USD
us-gaap Revenues
Revenues
12555000000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
289000000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
257000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
987000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
802000000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27000000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-77000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-52000000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
262000000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
233000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
910000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
750000000 USD

Files In Submission

Name View Source Status
0001179929-20-000139-index-headers.html Edgar Link pending
0001179929-20-000139-index.html Edgar Link pending
0001179929-20-000139.txt Edgar Link pending
R33.htm Edgar Link pending
0001179929-20-000139-xbrl.zip Edgar Link pending
exhibit21affinity-apa.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
moh-20200930.htm Edgar Link pending
moh-20200930.xsd Edgar Link pending
moh-20200930_cal.xml Edgar Link unprocessable
moh-20200930_def.xml Edgar Link unprocessable
moh-20200930_g1.jpg Edgar Link pending
moh-20200930_htm.xml Edgar Link completed
moh-20200930_lab.xml Edgar Link unprocessable
moh-20200930_pre.xml Edgar Link unprocessable
moh3q20ex311.htm Edgar Link pending
moh3q20ex312.htm Edgar Link pending
moh3q20ex321.htm Edgar Link pending
moh3q20ex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending